Canopy Growth Shares Surge 36% on Q2 Beat, Rolls Out Swiss THC Gummies & Canadian Vapes

Introduction

CANOPY GROWTH CORPORATION (Ticker: CGC) is a publicly traded cannabis company headquartered in Smiths Falls, Ontario. As of December 12, 2025, its shares are listed on the Nasdaq Global Select Market, trading at USD 1.5452 per share—an increase of 36.74% from the prior close—on a volume of 54,181,452 shares. The company develops, produces, and distributes cannabis and hemp products for medical and adult-use markets under a portfolio of brands that includes Tweed, 7ACRES, Doja, Deep Space, Claybourne, and Wana.

Corporate Structure

Founded in 2014, Canopy Growth employs between 1,001 and 5,000 people worldwide. Its corporate structure comprises:

• Canopy Growth Corp. (Canadian parent)
• Canopy USA, a separately operated holding company for U.S. assets (not consolidated into Canadian financials)
• Subsidiaries and Brand Units such as Spectrum Therapeutics (medical), Martha Stewart CBD (skincare), Storz & Bickel (vaporizers), and Wana Brands (edibles).

The company’s shares trade on the Toronto Stock Exchange under “WEED” and on Nasdaq under “CGC.” Odyssey Trust Company serves as its transfer agent.

Cannabis Products by CRYSTALWEED cannabis

Developments and News

• November 7, 2025: Canopy Growth reported its Q2 FY2026 results for the quarter ended September 30, 2025. The company indicated improvements in Adjusted EBITDA and disciplined cost management.
• December 2025: The “Days of Giving” program continued, with CEO Luc Mongeau and team members volunteering at Homes for Heroes in Kingston, Ontario.
• Early December 2025: Canopy USA announced the launch of Wana Brands’ THC gummies in Zurich, Switzerland, under the country’s regulated pilot program.
• Early December 2025: The Claybourne Co. introduced Gassers All-in-One vapes to the Canadian market, expanding its product offerings.
• November 2025: Spectrum Therapeutics expanded its medical portfolio in Australia with new softgel capsules.

Financial and Strategic Analysis

As of September 30, 2025 (TTM figures):

• Revenue: USD 278.61 million
• Net loss: USD 386.56 million
• Profit margin: –138.49%
• Return on equity: –62.06%
• Total cash (most recent quarter): USD 298.58 million
• Total debt/equity (most recent quarter): 35.23%
• Levered free cash flow: –USD 70.49 million
• Price/Sales (TTM): 1.04×
• Price/Book (most recent quarter): 0.74×

Management highlighted narrowed quarterly losses and margin improvements driven by operational enhancements within Canada’s adult-use and medical segments. The focus on cost management and effective capital allocation is aimed at sustaining progress in core markets while evaluating global expansion opportunities.

Market Position and Industry Context

Canopy Growth was among the first federally regulated, licensed cannabis producers in North America. It holds a significant share in Canada’s adult-use market while maintaining a presence in the medical market through Spectrum Therapeutics. The company has plans for the development of cannabis-infused beverages and other products, supported by partnerships, including an equity stake from Constellation Brands. Recent initiatives in Switzerland and Australia reflect its strategy to enter regulated markets. The industry continues to face challenges related to evolving regulations, excise tax reform debates, and competition from both licensed producers and illicit channels.

TL;DR

As of December 12, 2025, CGC shares trade at USD 1.5452 (+36.74%), driven by a rise following its November 7, 2025, Q2 FY2026 results. The company reported improved Adjusted EBITDA and cost management in Canadian adult-use and medical segments. In December 2025, Canopy teams participated in the Days of Giving program, while Claybourne Co. launched Gassers vapes in Canada and Wana Brands introduced THC gummies in Zurich. Spectrum Therapeutics added softgel capsules in Australia. Management's focus is on sustaining profitability trends and expanding into international markets.